GNS Healthcare is a precision medicine company based in Cambridge, Mass., led by Chairman, CEO and Co‑Founder Colin Hill. Its core product is the REFS causal learning and simulation platform, which analyzes data sets beyond correlation to infer causal mechanisms between variables. The platform is designed to answer questions such as how a patient will respond to a treatment and what would happen if one intervention is chosen over another. GNS targets health plans, biopharma companies, and health systems to address healthcare’s matching problem by transforming massive, diverse data streams to match therapeutics, procedures, and care-management interventions to individuals. Following its Series D, the company intends to use the funds to expand its business reach. GNS Healthcare develops REFS™ (Reverse Engineering & Forward Simulation), a patented causal machine learning and simulation platform that infers causal mechanisms from multimodal datasets and runs “what if?” simulations to predict individual treatment responses. The company delivers cloud-based solutions for health plans, biopharmaceutical companies, providers, foundations, academic medical centers, and self-insured employers. Customers use GNS to address problems including metabolic syndrome, medication adherence, end-of-life care, preterm birth, personalized specialty-care pathways, oncology, diabetes, new drug target discovery, and patient stratification in clinical trials. Led by Chairman and CEO and co-founder Colin Hill, GNS emphasizes using causality rather than correlation to guide interventions and therapeutic selection. The company plans to further develop REFS across drug discovery & development, value-based drug solutions, care management, and health‑system business optimization. The article reports a $6m equity investment to support those development efforts. GNS Healthcare applies patented causal machine learning and its REFS™ (Reverse Engineering and Forward Simulation) simulation engine along with the MeasureBase™ data integration architecture to analyze rich patient data streams. The company integrates electronic medical records, claims, genomics, mobile device data, and consumer behavior to identify individuals at risk and match them to the most effective interventions. Its cloud-based solutions are used by health plans, biopharmaceutical companies, healthcare providers, foundations, academic medical centers, and employers to address issues such as medication adherence, preterm birth, metabolic syndrome, and patient stratification in clinical trials. GNS focuses on reducing adverse events, slowing disease progression, and improving therapeutic effectiveness while lowering downstream medical costs. The company recently announced an investment from Horizon Healthcare Services to expand a strategic partnership and enable further development and validation of novel cloud-based precision-medicine solutions in population health. GNS Healthcare develops cloud-based, data-driven solutions that apply patented causal machine learning and its REFS™ (Reverse Engineering and Forward Simulation) engine to predict which treatments will work for which patients. The company integrates diverse patient data — including electronic medical records, mobile health devices, claims, genomics, and consumer behavior — to help health plans, biopharma, providers, foundations, academic researchers, and employers. Its platform (MAX™ data architecture and REFS™ engine) is used for patient stratification, comparative effectiveness, drug target discovery, addressing medication non-adherence, preterm birth, end-of-life care, metabolic syndrome, diabetes, and specialty care. GNS licenses these solutions to customers and aims to accelerate development of new cloud-based big data offerings at the intersection of precision medicine and population health. The company emphasizes using causal inference and simulation to reveal cause-and-effect relationships and to support point-of-care and research decision-making. GNS has been active in the precision medicine movement since 2000 and positions its technology to improve outcomes while reducing costs. GNS Healthcare develops patented big data analytics methods to build predictive models and products for pharmaceutical companies, health plans and providers. Its tools address population health management questions such as predicting individual and population risk and costs, comparing treatment effectiveness, targeting member engagement to improve medication adherence, and discovering biomarkers that predict patient response to medications. Led by CEO Colin Hill, the company sells analytics products and services across the healthcare sector. GNS completed a $10M Series B financing and intends to use the funds to expand its data analytics business across the healthcare industry. The company is based in Cambridge, MA.

Total raised

$49M

Funding rounds

5

Latest round

Series D

Latest activity

Jul 2019